Our results demonstrating increased expression of PD-L2, CD80, and CD86 in aggressive pituitary adenoma samples provide a rationale for studying whether immune checkpoint blockade is effective for tumor control. This evidence concerns the gene CD86 and pituitary gland adenoma.